J. Lipid Res. Did you know there is a large type edition? Click here.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.M500144-JLR200 on September 8, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M500144-JLR200v1
46/11/2325    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pütz, G.
Right arrow Articles by Blum, H. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pütz, G.
Right arrow Articles by Blum, H. E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 46, 2325-2338, November 2005
Copyright © 2005 by American Society for Biochemistry and Molecular Biology

Synthesis of phospholipid-conjugated bile salts and interaction of bile salt-coated liposomes with cultured hepatocytes1

G. Pütz2,*, W. Schmider{dagger}, R. Nitschke§, G. Kurz*,1 and H. E. Blum*

* University Medical Clinic Freiburg, D-79106 Freiburg, Germany
{dagger} Aventis Pharma Germany GmbH, Sanofi-Aventis Group, D-65929 Frankfurt/M, Germany
§ Life Imaging Center, Institute of Biology I, University of Freiburg, D-79104 Freiburg, Germany

1 This paper is dedicated to the memory of Prof. Dr. G. Kurz, deceased May 29, 2002.

Published, JLR Papers in Press, September 8, 2005. DOI 10.1194/jlr.M500144-JLR200

2 To whom correspondence should be addressed. e-mail: puetz{at}medizin.ukl.uni-freiburg.de

To examine the possibility of targeting liposomes to hepatocytes via bile salts, the bile salt lithocholyltaurine was covalently linked to a phospholipid. The isomeric compounds disodium 3{alpha}-(2-(1,2-O-distearoyl-sn-glycero-3-phospho-2'-ethanolamidosuccinyloxy)ethoxy)-5ß-cholan-24-oyl-2'-aminoethansulfonate and disodium 3ß-(2-(1,2-O-distearoyl-sn-glycero-3-phospho-2'-ethanolamidosuccinyloxy)ethoxy-5ß-cholan-24-oyl-2'-aminoethansulfonate (DSPE-3ß-LCT) were synthesized and incorporated into liposomal membranes. Confocal laser scanning microscopy studies showed that bile salt-bearing liposomes (BSLs) attach to the surface of rat hepatocytes in culture. Studies with radioactively labeled liposomes revealed that the bile salt linked via the 3ß-conformation resulted in a higher attachment efficiency than that with the 3{alpha}-derivative. In the presence of BSLs corresponding to 2 mM liposomal phosphatidylcholine, uptake of 50 µM cholyltaurine (CT) into hepatocytes was reduced by ~40% by the 3ß-derivative and by ~17% by the 3{alpha}-derivative. When added simultaneously with the liposomes, CT up to 75 µM inhibited the binding of DSPE-3ß-LCT-bearing liposomes. By contrast, increasing concentrations reversed this inhibition and resulted in an increased bile salt-mediated binding. The same was true when CT was added 10 min before the liposomes were added.

The attachment of BSLs to the surface of hepatocytes opens up promising possibilities for hepatocyte-specific drug delivery. More generally, not only substrates for cellular endocytosing receptors but also substrates for cellular carrier proteins should be suitable ligands for the cell-specific targeting of nanoscale particles such as liposomes.

Abbreviations: BSL, bile salt-bearing liposome; CH, cholesterol; COL, control liposome; CT, cholyltaurine; DCCI, N,N'-dicyclohexylcarbodiimide; DPPC, 1,2-O-dipalmitoyl-sn-glycero-3-phosphocholine; DPPS, 1,2-O-dipalmitoyl-sn-glycero-3-phosphoserine; DSPE, 1,2-O-distearoyl-sn-glycero-3-phosphoethanolamine; DSPE-3-LCT, disodium 3-(2-(1,2-O-distearoyl-sn-glycero-3-phospho-2'-ethanolamidosuccinyloxy)ethoxy)-5ß-cholan-24-oyl-2'-aminoethansulfonate; DSPE-3{alpha}-LCT, disodium 3{alpha}-(2-(1,2-O-distearoyl-sn-glycero-3-phospho-2'-ethanolamidosuccinyloxy)ethoxy)-5ß-cholan-24-oyl-2'-aminoethansulfonate; DSPE-3ß-LCT, disodium 3ß-(2-(1,2-O-distearoyl-sn-glycero-3-phospho-2'-ethanolamidosuccinyloxy) ethoxy-5ß-cholan-24-oyl-2'-aminoethansulfonate; DSPG, 1,2-O-distearoyl-sn-glycero-3-phospho-rac-(1-glycerol); LSM, laser scanning microscopy; NBD, 4-nitrobenzo-2-oxa-1, 3-diazol; MP, melting point; MS, mass spectrum; Ntcp, Na+/cholyltaurine-cotransporting polypeptide; PC, phosphatidylcholine; Ph2-DiOC18, 3,3'-dioctadecyl-5,5'-diphenyloxacarbocyanine chloride; PSL, phosphatidylserine-bearing liposome; RT, room temperature; SS, solvent system

Supplementary key words hepatic drug delivery • bile salt carrier • modified liposomes • hepatocyte-specific drug targeting


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.